Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
RTKI drugs may not significantly improve survival rates of patients during radiotherapy

RTKI drugs may not significantly improve survival rates of patients during radiotherapy

Raman microscopy can help detect cancer drug resistance

Raman microscopy can help detect cancer drug resistance

Researchers propose novel theory of how some cancers circumvent killing power of targeted therapies

Researchers propose novel theory of how some cancers circumvent killing power of targeted therapies

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

New tool could help identify patients most likely to benefit from chemoprevention

New tool could help identify patients most likely to benefit from chemoprevention

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

Researchers identify multiple types of resistance to new targeted lung cancer drug

Researchers identify multiple types of resistance to new targeted lung cancer drug

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Personalized treatment may be effective in wild type cancers

Personalized treatment may be effective in wild type cancers

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Chemotherapy best second-line option for EGFR wild-type NSCLC

Chemotherapy best second-line option for EGFR wild-type NSCLC

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug